Profile data is unavailable for this security.
About the company
DNA Group TR Ltd, former DNA Biomedical Solutions Ltd, is an Israel-based company, which is engaged in the biotechnology sector. The Company's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltd’s proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltd’s drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.
- Revenue in ILS (TTM)306.00k
- Net income in ILS-1.18m
- Incorporated2004
- Employees14.00
- LocationDNA Group (T.R.) LtdSHIM'ON HATARSI 43TEL AVIV-YAFO 62492IsraelISR
- Phone+972 35462550
- Fax+972 35462570
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextage Therapeutics Ltd | 876.00k | -4.07m | 21.29m | -- | -- | -- | -- | 24.31 | -0.1396 | -0.1396 | 0.03 | -0.0958 | 0.672 | -- | 6.82 | -- | -322.44 | -188.94 | -- | -423.76 | 25.68 | 33.33 | -479.79 | -2,486.19 | -- | -18.46 | -- | -- | -- | 17.99 | 27.21 | -- | -- | -- |
| Kadimastem Ltd | 0.00 | -12.01m | 26.11m | 32.00 | -- | -- | -- | -- | -1.22 | -1.22 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -115.17 | -155.33 | -1,153.60 | -1,831.12 | -- | -- | -- | -- | -- | -9.44 | 3.22 | -- | -- | -- | 47.14 | -- | -50.73 | -- |
| Purple Biotech Ltd | 0.00 | -67.90m | 47.78m | 20.00 | -- | 0.3811 | -- | -- | -0.2679 | -0.2679 | 0.00 | 0.4086 | 0.00 | -- | -- | 0.00 | -40.57 | -37.24 | -47.99 | -41.28 | -- | -- | -- | -9,415.70 | -- | -- | 0.0098 | -- | -- | -- | 8.25 | -- | -28.45 | -- |
| X T L Biopharmaceuticals Ltd | 1.64m | -81.38m | 48.73m | 33.00 | -- | 0.599 | -- | 29.66 | -0.3695 | -0.3695 | 0.0075 | 0.1493 | 0.0192 | -- | 0.7012 | 49,784.54 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| Matricelf Ltd | 0.00 | -13.83m | 57.22m | -- | -- | 2.12 | -- | -- | -0.8777 | -0.8777 | 0.00 | 1.67 | 0.00 | -- | -- | -- | -39.69 | -- | -42.80 | -- | -- | -- | -- | -- | -- | -- | 0.0527 | -- | -- | -- | -10.77 | -- | -- | -- |
| DNA Group TR Ltd | 306.00k | -1.18m | 87.20m | 14.00 | -- | 1.10 | -- | 284.97 | -0.0088 | -0.0088 | 0.0025 | 0.6429 | 0.0038 | -- | 1.37 | 21,857.14 | -1.45 | -23.54 | -1.46 | -26.27 | -- | -- | -384.64 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| Bonus Biogroup Ltd | 0.00 | -28.84m | 178.69m | 58.00 | -- | 8.13 | -- | -- | -0.0675 | -0.0675 | 0.00 | 0.0188 | 0.00 | -- | -- | 0.00 | -54.73 | -76.10 | -63.36 | -97.19 | -- | -- | -- | -- | -- | -- | 0.331 | -- | -- | -- | 26.29 | -- | 19.30 | -- |
| BioLine RX Ltd | 42.18m | -177.85m | 208.43m | 79.00 | -- | 4.00 | -- | 4.94 | -0.184 | -0.184 | 0.042 | 0.0435 | 0.1939 | -- | 6.40 | 533,872.80 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sigma Mutual Funds Ltd.as of 31 Mar 2024 | 438.09k | 0.36% |
| Meitav Mutual Funds Ltd.as of 31 Mar 2024 | 111.36k | 0.09% |
| Migdal Mutual Funds Ltd.as of 30 Apr 2024 | 40.73k | 0.03% |
| KSM Mutual Funds Ltd.as of 30 Apr 2024 | 40.32k | 0.03% |
| Sigma PCM Mutual Funds Management Co. Ltd.as of 31 Mar 2024 | 28.12k | 0.02% |
| Psagot Mutual Funds Ltd.as of 30 Apr 2024 | 10.52k | 0.01% |
| Harel Mutual Funds Ltd.as of 30 Apr 2024 | 3.54k | 0.00% |
